<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04485013</url>
  </required_header>
  <id_info>
    <org_study_id>TTX-080-001</org_study_id>
    <nct_id>NCT04485013</nct_id>
  </id_info>
  <brief_title>TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers</brief_title>
  <official_title>A First-in-human, Phase 1 Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tizona Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tizona Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, multicenter, open-label, multiple-dose, dose-escalation and dose-expansion
      study to evaluate the safety, tolerability, PK, and pharmacodynamics of TTX-080 monotherapy
      in subjects with advanced or metastatic solid tumors known to express HLA-G.

      This first-in-human (FIH) study has been designed to evaluate the safety, tolerability, and
      preliminary antitumor activity of TTX-080 as monotherapy in adults with unresectable or
      metastatic solid tumors known to express HLA-G.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>1 cycle (each cycle is 21 days)</time_frame>
    <description>To assess safety and tolerability of increasing dose levels of TTX-080 in successive cohorts of subjects with advanced solid tumors to identify the maximum tolerated dose (MTD) or maximum administered dose and select the recommended Phase 2 dose (RP2D)/schedule</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Serum concentrations of TTX-080 will be tabulated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Serum levels of antidrug antibody (ADA) against TTX-080</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measure the proportion of subjects with ORR, DoR, and PFS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Monotherapy Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTX-080</intervention_name>
    <description>Variable dose (Q3W)</description>
    <arm_group_label>Monotherapy Dose Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Abbreviated Inclusion Criteria:

          1. Subject with histological or cytological diagnosis of advanced/metastatic cancer

          2. Age 18 years or older, is willing and able to provide informed consent

          3. Evidence of measurable disease

          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

        Abbreviated Exclusion Criteria:

          1. History of allergy or hypersensitivity to study treatment components. Subjects with a
             history of severe hypersensitivity reaction to any monoclonal antibody

          2. Use of investigational agent within 28 days prior to the first dose of study treatment
             and throughout the study

          3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive
             therapy

          4. History of severe autoimmune disease

          5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tizona Therapeutics, Inc.</last_name>
    <phone>888-585-2990</phone>
    <email>clinicaltrials@tizonatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Gomez</last_name>
      <phone>210-580-9521</phone>
      <email>sgomez@nextsat.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HLA-G</keyword>
  <keyword>TTX-080</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Kidney Cancer</keyword>
  <keyword>Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>Squamous Cell Lung Cancer</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Bladder Cancer</keyword>
  <keyword>Lung Adenocarcinoma</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Metastatic Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

